These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23391120)

  • 1. A 75-year-old man with progressive bronchioalveolar carcinoma.
    Baikadi M; Lovly C; Horn L; Reckamp KL; Noonan K; Laskin J; Morris GJ
    Semin Oncol; 2013 Feb; 40(1):e1-8. PubMed ID: 23391120
    [No Abstract]   [Full Text] [Related]  

  • 2. [Importance of pathology research on lung adenocarcinoma].
    Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):649-51. PubMed ID: 23302303
    [No Abstract]   [Full Text] [Related]  

  • 3. Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
    Thomas A; Xi L; Carter CA; Rajan A; Khozin S; Szabo E; Dennis PA; Giaccone G; Raffeld M
    Clin Lung Cancer; 2013 Jul; 14(4):452-6. PubMed ID: 23540867
    [No Abstract]   [Full Text] [Related]  

  • 4. Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis.
    von der Thüsen JH; van de Wetering MD; Westermann AM; Heideman DA; Thunnissen E
    J Clin Oncol; 2011 Mar; 29(8):e188-90. PubMed ID: 21189386
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
    Smit EF; Dingemans AM; Thunnissen FB; Hochstenbach MM; van Suylen RJ; Postmus PE
    J Thorac Oncol; 2010 May; 5(5):719-20. PubMed ID: 20421765
    [No Abstract]   [Full Text] [Related]  

  • 6. Mucinous bronchioloalveolar carcinoma with K-ras mutation arising in type 1 congenital cystic adenomatoid malformation: a case report with review of the literature.
    Ishida M; Igarashi T; Teramoto K; Hanaoka J; Iwai M; Yoshida K; Kagotani A; Tezuka N; Okabe H
    Int J Clin Exp Pathol; 2013; 6(11):2597-602. PubMed ID: 24228126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology matters: individualizing treatment in non-small cell lung cancer.
    Neal JW
    Oncologist; 2010; 15(1):3-5. PubMed ID: 20086166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
    Glynn C; Zakowski MF; Ginsberg MS
    J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchioloalveolar neoplasia.
    Kitamura H; Okudela K
    Int J Clin Exp Pathol; 2010 Nov; 4(1):97-9. PubMed ID: 21228931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
    Kaira K; Horie Y; Ayabe E; Murakami H; Takahashi T; Tsuya A; Nakamura Y; Naito T; Endo M; Kondo H; Nakajima T; Yamamoto N
    J Thorac Oncol; 2010 Apr; 5(4):460-5. PubMed ID: 20107421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
    Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
    Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
    Chung JH; Choe G; Jheon S; Sung SW; Kim TJ; Lee KW; Lee JH; Lee CT
    J Thorac Oncol; 2009 Dec; 4(12):1490-5. PubMed ID: 19844187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.
    Mackinnon AC; Tretiakova M; Henderson L; Mehta RG; Yan BC; Joseph L; Krausz T; Husain AN; Reid ME; Salgia R
    J Clin Pathol; 2011 Jan; 64(1):16-24. PubMed ID: 21045234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit origin.
    Park WY; Kim MH; Shin DH; Lee JH; Choi KU; Kim JY; Park DY; Lee CH; Sol MY
    Mod Pathol; 2012 Sep; 25(9):1265-74. PubMed ID: 22555174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
    Sholl LM; Yeap BY; Iafrate AJ; Holmes-Tisch AJ; Chou YP; Wu MT; Goan YG; Su L; Benedettini E; Yu J; Loda M; Jänne PA; Christiani DC; Chirieac LR
    Cancer Res; 2009 Nov; 69(21):8341-8. PubMed ID: 19826035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
    J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.
    Ortiz TM; Cohen DW; Kent MS; Jänne PA; Costa DB
    J Thorac Oncol; 2011 Jan; 6(1):220-2. PubMed ID: 21178719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.